Radioiodine therapy in advanced differentiated thyroid cancer: Resistance and overcoming strategy

Liu, Yujia; Wang, Jiafeng; Hu, Xiaoping; Pan, Zongfu; Xu, Tao; Xu, Jiajie; Jiang, Liehao; Huang, Ping; Zhang, Yiwen; Ge, Minghua

doi:10.1016/j.drup.2023.100939

Cited by 16 publications

(9 citation statements)

References 245 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, not all PTC patients respond optimally to RAI therapy, and some develop resistance to its effects. Resistance to RAI therapy in PTC is a complex phenomenon with various proposed mechanisms ( 32 ). There are several key factors contributing to PTC RAI resistance.…”

Section: Discussionmentioning

confidence: 99%

Global research landscape and trends of papillary thyroid cancer therapy: a bibliometric analysis

Song,

Lin,

Feng

et al. 2023

Front. Endocrinol.

View full text Add to dashboard Cite

BackgroundPapillary thyroid cancer (PTC) is the most common endocrine malignancy worldwide. The treatment of PTC has attracted extensive attention and discussion from the public and scholars. However, no article has systematically assessed the related literature. Therefore, we conducted a bibliometric and knowledge map analysis to reveal the dynamic scientific developments in the PTC therapy field.MethodsWe retrieved publications related to PTC therapy from the Web of Scientific Core Collection (WoSCC) on May 1, 2023. The bibliometric package in R software, VOSviewer and CiteSpace software were used to analyze countries/regions, institutions, journals, authors, references, and keywords. Then, we systematized and summarized the research landscape, global trends and hot topics of research.ResultsThis bibliometric analysis spanned from 2012 to 2022 and involved 18,501 authors affiliated with 3,426 institutions across 87 countries/regions, resulting in the publication of 3,954 papers in 860 academic journals. Notably, the number of publications and citations related to PTC therapy research has exhibited a steady increase over the past decade. China and the United States have emerged as leading contributors in terms of publication count, with the United States also being the most cited country. Furthermore, among the top 10 institutions with the highest number of published papers, half were located in China. Among the journals, Thyroid is ranked first in terms of total publications and citations. The most productive individual author was Miyauchi Akira. While previous research primarily focused on surgery and radioactive iodine therapy, the increasing emphasis on health awareness and advancements in medical technology have led to the emergence of active surveillance, thermal ablation, and genomic analysis as prominent areas of research.ConclusionIn conclusion, this comprehensive and quantitative bibliometric analysis elucidates the research trends and hotspots within PTC therapy, drawing from a substantial body of publications. This study provides valuable insights into the historical and current landscape of PTC therapy research while also offering guidance for future research directions. This study serves as a valuable resource for researchers and practitioners seeking new avenues of exploration in the field.

show abstract

Section: Discussionmentioning

confidence: 99%

Global research landscape and trends of papillary thyroid cancer therapy: a bibliometric analysis

Song,

Lin,

Feng

et al. 2023

Front. Endocrinol.

View full text Add to dashboard Cite

show abstract

“…However, up to 20% and 10% of those with PTC will present with local recurrence and distant metastasis, respectively. Among these patients, two-thirds exhibit initial or gradual loss of the iodine uptake, indicating a status of dedifferentiation with limited effective treatment, which is known as being lethal for its less than 10% 10-yr survival rate ( Ma et al, 2019 ; Ulisse et al, 2021 ; Liu et al, 2023 ). Clinically, precise diagnostic targets and efficient therapeutic methods for these patients are still insufficient.…”

Section: Discussionmentioning

confidence: 99%

tRF-1:30-Gly-CCC-3 inhibits thyroid cancer via binding to PC and modulating metabolic reprogramming

Fu,

Lou,

et al. 2023

Life Sci. Alliance

View full text Add to dashboard Cite

tRFs and tiRNAs (tRNA-derived fragments) are an emerging class of small noncoding RNAs produced by the precise shearing of tRNAs in response to specific stimuli. They have been reported to regulate the pathological processes of numerous human cancers. However, the biofunction of tRFs and tiRNAs in the development and progression of papillary thyroid cancer (PTC) has not been reported yet. In this study, we aimed to explore the biological roles of tRFs and tiRNAs in PTC and discovered that a novel 5′tRNA-derived fragment called tRF-1:30-Gly-CCC-3 (tRF-30) was markedly down-regulated in PTC tissues and cell lines. Functionally, tRF-30 inhibited the proliferation and invasion of PTC cells. Mechanistically, tRF-30 directly bound to the biotin-dependent enzyme pyruvate carboxylase (PC), downregulated its protein level, interfered with the TCA cycle intermediate anaplerosis, and thus affected metabolic reprogramming and PTC progression. These findings revealed a novel regulatory mechanism for tRFs and a potential therapeutic target for PTC.

show abstract

“…Thyroidectomy and radioactive iodine therapy have become the mainstay of treatment for TC. Patients with DTC without local progression and local/distant metastases can usually achieve better outcomes with surgery and radioactive iodine (RAI) therapy ( Liu et al, 2023 ). Nonetheless, the rates of structural recurrence (locoregional or distant metastases) in low-risk, intermediate-risk, and high-risk patients are 3%–13%, 21%–36%, and 68%, respectively, and patients are classified by the American Thyroid Association risk stratification criteria ( Coca-Pelaz et al, 2023 ).For patients with unresectable or metastatic DTC, RAI therapy is considered the primary therapeutic approach.…”

Section: Thyroid Cancer Treatment and Challengesmentioning

confidence: 99%

Research progress of plant-derived natural products in thyroid carcinoma

Du,

Shen

2024

Front. Chem.

View full text Add to dashboard Cite

Thyroid carcinoma (TC) is a prevalent malignancy of the endocrine system, with a notable rise in its detection rate in recent decades. The primary therapeutic approaches for TC now encompass thyroidectomy and radioactive iodine therapy, yielding favorable prognoses for the majority of patients. TC survivors may necessitate ongoing surveillance, remedial treatment, and thyroid hormone supplementation, while also enduring the adverse consequences of thyroid hormone fluctuations, surgical complications, or side effects linked to radioactive iodine administration, and encountering enduring physical, psychosocial, and economic hardships. In vitro and in vivo studies of natural products against TC are demonstrating the potential of these natural products as alternatives to the treatment of thyroid cancer. This therapy may offer greater convenience, affordability, and acceptability than traditional therapies. In the early screening of natural products, we mainly use a combination of database prediction and literature search. The pharmacological effects on TC of selected natural products (quercetin, genistein, apigenin, luteolin, chrysin, myricetin, resveratrol, curcumin and nobiletin), which hold promise for therapeutic applications in TC, are reviewed in detail in this article through most of the cell-level evidence, animal-level evidence, and a small amount of human-level evidence. In addition, this article explores possible issues, such as bioavailability, drug safety.

show abstract

Radioiodine therapy in advanced differentiated thyroid cancer: Resistance and overcoming strategy

Cited by 16 publications

References 245 publications

Global research landscape and trends of papillary thyroid cancer therapy: a bibliometric analysis

Global research landscape and trends of papillary thyroid cancer therapy: a bibliometric analysis

tRF-1:30-Gly-CCC-3 inhibits thyroid cancer via binding to PC and modulating metabolic reprogramming

Research progress of plant-derived natural products in thyroid carcinoma

Contact Info

Product

Resources

About